Navigation Links
Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
Date:9/16/2008

ome technology licensed from Pevion Biotech Ltd. Mymetics' vaccine approach focuses on eliciting immune protection capable of interfering with late events of pathogen transmission, a generally accepted approach coupled, uniquely and most importantly, with early events of pathogen transmission, such as preventing virus entry across the mucosal tissues, the primary entry door of most pathogens. Virosomes are lipidic vesicles derived from influenza virus membrane that are non-replicative antigen carriers which possess intrinsic systemic and mucosal adjuvant properties. Virosomes are approved in 42 countries and have been used since 1994 for two vaccines in over 40 million doses with no significant side effects. The Company's disease focus presently includes malaria and the human immunodeficiency virus.

For further information regarding the Company and its mucosal approach, please visit http://www.mymetics.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking statements."Such forward-looking statements are sometimes identified by words such as "intends,""anticipates,""believes,""expects" and "hopes."The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings
'/>"/>

SOURCE Mymetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
4. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
8. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... WESTLAKE VILLAGE, Calif. , July 27, 2015 ... KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH ) today announced ... early termination of the waiting period under the Hart-Scott-Rodino ... to Allergan,s pending acquisition of KYTHERA.  ... 6, 2015, each of Allergan and KYTHERA filed a ...
(Date:7/27/2015)... , July 20, 2015 ... addition of the "Global Pressure Relief Devices Market ... Global Pressure Relief Devices market to grow at a ... report, Global Pressure Relief Devices Market 2015-2019, has been ... from industry experts. The report covers the Americas, and ...
(Date:7/27/2015)... , July 27, 2015  Attorney Advertising-- Bronstein, ... on behalf of purchasers of the securities of ... AMAG -News).  Such investors are advised to contact ... coordinator Eitan Kimelman at info@bgandg.com ... whether AMAG and certain of its officers and/or ...
Breaking Medicine Technology:Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2
... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWAD ... financial results for the second quarter ended June 30th, ... 2010, the Company,s quarterly net sales increased 106% to ... period in 2009, driven by growth in prescription and ...
... CORAL SPRINGS, Fla., Aug. 17 VirtuOx, Inc., ... in delivering home sleep testing solutions, today announced ... products and services company currently servicing the sleep-disordered ... in its portfolio, the VirtuOx Home Sleep Test ...
Cached Medicine Technology:HealthWarehouse.com Reports 106% Revenue Growth in the Second Quarter 2010 Compared to 2009 2VirtuOx and Watermark Medical Announce Strategic Alliance to Expand Sleep Apnea Home Sleep Testing Solutions 2VirtuOx and Watermark Medical Announce Strategic Alliance to Expand Sleep Apnea Home Sleep Testing Solutions 3
(Date:7/27/2015)... ... ... Dr. Robert G. Schwartz , principal of Greenville, SC-based Piedmont Physical ... Centers in order to offer his patients a new system of care utilizing laser ... , Peripheral neuropathy is a disease caused by damage to the peripheral nerves, and ...
(Date:7/27/2015)... , ... July 28, 2015 , ... Combination Product GMP ... – 3:00 p.m. EDT, http:// http://www.fdanews.com/comboproductgmpcompliance , Manufacturing a drug ... of combination products things can get messy in a hurry. In a 46-page draft ...
(Date:7/27/2015)... ... July 28, 2015 , ... Recently, the Anderson ... medicine provider for the entire school district including Anderson County Middle School (ACMS) ... Rick Sallee, “Student safety and well-being are a top priority for us in ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of Professional Women ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... NAPW is the nation’s leading networking organization exclusively for professional women. , “I’m pleased ...
(Date:7/27/2015)... Garden City, NY (PRWEB) , ... July 28, 2015 , ... ... as a 2015-2016 inductee into the NAPW VIP Woman of the Year Circle. ... 700,000 members and over 200 operating Local Chapters, NAPW is the nation’s leading networking ...
Breaking Medicine News(10 mins):Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 4Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2Health News:NAPW Inducts Jane Simmons, Counseling Intern at Omar Bradley Middle School of the Northeast Independent School District , Into its VIP Woman of the Year Circle 2
... Contest ... ... -- InSound Medical , manufacturer and developer of Lyric®, the first 100 percent invisible, ... Lyric Hearing Story" Contest. Lyric wearers have the opportunity to win a free year ...
... , SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ ... announced that its board of directors has declared a third quarter 2009 ... equivalent to an annualized dividend of $0.44 per common share. , ... has declared a dividend of $0.46094 per share of the company,s 7.375% ...
... , THOUSAND OAKS, Calif., Sept. 15 ... the Court of Appeals for the Federal Circuit affirmed the ... four Amgen patents (,868, ,698, ,933 and ,422) relating to ... a fifth patent (,349), the Federal Circuit reversed the holding ...
... Approval Provides Important Tool to Fight Pandemic , , ... announced today that it has approved four vaccines against the 2009 H1N1 ... become available, which is expected within the next four weeks. , ... , , "Today,s approval is good news for our ...
... big reason why, researchers say , TUESDAY, Sept. 15 ... the hospital are much less likely to survive than white ... appears to result from the hospital in which black patients ... the researchers said. , "We know that survival after having ...
... , WASHINGTON, Sept. 15 The American ... impact on health care issues conducted by Pulse Opinion Research, LLC, ... of Americans believe that high immigration levels have had an adverse ... Republicans (89%) felt more strongly on the issue, but Democrats ...
Cached Medicine News:Health News:InSound Medical Kicks Off "Tell Us Your Story" Contest 2Health News:BioMed Realty Trust Declares Third Quarter 2009 Common Stock and Preferred Stock Dividends 2Health News:Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product 2Health News:FDA Approves Vaccines for 2009 H1N1 Influenza Virus 2Health News:FDA Approves Vaccines for 2009 H1N1 Influenza Virus 3Health News:Blacks Fare Worse After Cardiac Arrest 2Health News:Blacks Fare Worse After Cardiac Arrest 3Health News:National Poll Finds Most Americans Believe Immigration Adversely Affects the Quality and Cost of Healthcare 2
... kit is an enzymeimmunoassay for the quantitation ... in serum or plasma. Calibrators, controls and ... D. The diluted samples are incubated in ... highly specific sheep 25-OH D antibody for ...
... responsible for the control of glucose metabolism. ... islets of Langerhans as the precursor, proinsulin, which ... Both are secreted in equimolar amounts into the ... comprised of two polypeptide chains, the A-chain and ...
... Angiotensin Converting Enzyme (ACE) is an integral ... the generation of Angiotensin II as well ... many different cell types, ACE is primarily ... only an important diagnostic parameter for sarcoidosis ...
... (RBP) is small (21kD) transport protein for ... in blood but loses its affinity for,prealbumin ... the target cells. The free,RBP molecule is ... catabolized in the,renal tubules after resorption by ...
Medicine Products: